NUR 318 Women's Health Exam 1 Women's
Health Nursing Assessment | 2026/2027
Edition Comprehensive Examination
Introduction
This comprehensive examination document is specifically designed for
students preparing for the NUR 318 Women's Health Examination (Exam 1)
for the 2026/2027 academic cycle. The content is structured around the
official course blueprint, encompassing all critical domains: Women's Health
Assessment, Anatomy and Physiology, Reproductive Health, Menstrual Cycle
and Endocrine Function, Contraception, Family Planning and STI
Management, Benign Gynecological Disorders and Conditions, and Health
Promotion, Ethics and Cultural Considerations. Each of the 85 questions has
been expertly verified to reflect current evidence-based standards, ACOG
clinical guidelines, CDC STI treatment guidelines, and women's health nursing
standards for 2026/2027. This document provides 100% verified correct
answers with detailed rationales, designed to ensure accurate self-evaluation
and pass-level readiness for the actual examination.
Key Features
• ✓ 85-Question Comprehensive Exam matching NUR 318 format
• ✓ Women's Health Assessment, Anatomy & Physiology
• ✓ Reproductive Health, Menstrual Cycle & Endocrine Function
• ✓ Contraception, Family Planning & STI Management
• ✓ Benign Gynecological Disorders & Conditions
• ✓ Health Promotion, Ethics & Cultural Considerations
• ✓ Detailed rationales for each answer to enhance learning
• ✓ Updated 2026/2027 ACOG, CDC, and WHO standards
,Content Area Overview
Content Area Questions Key Topics Weight
Reproductive anatomy,
Women's Health
menstrual cycle, hormones,
Assessment,
1-18 clinical breast exam, 21%
Anatomy &
Pap/HPV screening, ACOG
Physiology
2026 guidelines
Reproductive Menarche, PMS, PCOS,
Health, Menstrual endometriosis, amenorrhea,
Cycle & 19-35 ovulation, menopause 20%
Endocrine transition, Rotterdam
Function criteria
LARC, COCs, EC,
Contraception,
chlamydia/gonorrhea, BV,
Family Planning
36-54 trichomoniasis, HSV, HPV, 22%
& STI
condoms, CDC 2026
Management
guidelines
Fibroids, ovarian cysts,
Benign
endometriosis, prolapse,
Gynecological
55-71 Bartholin cyst, 20%
Disorders &
postmenopausal bleeding,
Conditions
Pap results
Health Cultural competence, CVD
Promotion, Ethics prevention, folic acid, female
72-85 17%
& Cultural athlete triad, adolescent
Considerations consent, HT, bone health
,Content Area Questions Key Topics Weight
TOTAL 85 Comprehensive Coverage 100%
Question 1
According to the 2026 ACOG cervical cancer screening guidelines, what is the
recommended screening approach for average-risk individuals aged 30-65
years?
A) Cervical cytology alone every 3 years
B) Primary high-risk HPV (hrHPV) screening every 5 years
C) Co-testing with cytology and HPV every 5 years
D) Annual cervical cytology
Rationale: According to the 2026 ACOG cervical cancer screening guidance,
individuals aged 30-65 years should undergo clinician-collected primary
hrHPV screening every 5 years, using FDA-approved tests. This represents a
shift from cytology-based to HPV-first screening strategies.
Question 2
For average-risk individuals aged 21-29 years, what is the current ACOG
recommendation for cervical cancer screening?
A) Cervical cytology alone every 3 years
B) Primary HPV screening every 5 years
C) Co-testing every 5 years
D) Annual screening
Rationale: The 2026 ACOG guidelines recommend that individuals aged 21-
29 years be screened with cervical cytology alone every 3 years. HPV
screening is not recommended as the primary method for this age group due
to the high rate of transient HPV infections that resolve spontaneously.
, Question 3
Which patient population is eligible for patient-collected samples for primary
HPV testing under the 2026 ACOG guidelines?
A) All patients aged 21-65 years
B) Average-risk patients aged 30-65 years
C) Patients with abnormal Pap results only
D) Patients with multiple sexual partners
Rationale: The 2026 ACOG guidelines include the option for average-risk
patients aged 30-65 years to collect their own samples for hrHPV primary
screening every 3 years. This is a significant update aimed at improving access
and equity in cervical cancer screening.
Question 4
What is the primary purpose of a clinical breast examination (CBE) in
women's health assessment?
A) To diagnose breast cancer definitively
B) To detect breast abnormalities and serve as an adjunct to screening
mammography
C) To replace mammography
D) To screen for ovarian cancer
Rationale: Clinical breast examination is performed to detect breast
abnormalities such as masses, skin changes, or nipple discharge. It serves as
an adjunct to screening mammography, not a replacement. Definitive
diagnosis requires biopsy and further testing.
Question 5
Which hormone is responsible for the proliferation of the endometrial lining
during the proliferative phase of the menstrual cycle?
A) Progesterone
B) Estrogen
Health Nursing Assessment | 2026/2027
Edition Comprehensive Examination
Introduction
This comprehensive examination document is specifically designed for
students preparing for the NUR 318 Women's Health Examination (Exam 1)
for the 2026/2027 academic cycle. The content is structured around the
official course blueprint, encompassing all critical domains: Women's Health
Assessment, Anatomy and Physiology, Reproductive Health, Menstrual Cycle
and Endocrine Function, Contraception, Family Planning and STI
Management, Benign Gynecological Disorders and Conditions, and Health
Promotion, Ethics and Cultural Considerations. Each of the 85 questions has
been expertly verified to reflect current evidence-based standards, ACOG
clinical guidelines, CDC STI treatment guidelines, and women's health nursing
standards for 2026/2027. This document provides 100% verified correct
answers with detailed rationales, designed to ensure accurate self-evaluation
and pass-level readiness for the actual examination.
Key Features
• ✓ 85-Question Comprehensive Exam matching NUR 318 format
• ✓ Women's Health Assessment, Anatomy & Physiology
• ✓ Reproductive Health, Menstrual Cycle & Endocrine Function
• ✓ Contraception, Family Planning & STI Management
• ✓ Benign Gynecological Disorders & Conditions
• ✓ Health Promotion, Ethics & Cultural Considerations
• ✓ Detailed rationales for each answer to enhance learning
• ✓ Updated 2026/2027 ACOG, CDC, and WHO standards
,Content Area Overview
Content Area Questions Key Topics Weight
Reproductive anatomy,
Women's Health
menstrual cycle, hormones,
Assessment,
1-18 clinical breast exam, 21%
Anatomy &
Pap/HPV screening, ACOG
Physiology
2026 guidelines
Reproductive Menarche, PMS, PCOS,
Health, Menstrual endometriosis, amenorrhea,
Cycle & 19-35 ovulation, menopause 20%
Endocrine transition, Rotterdam
Function criteria
LARC, COCs, EC,
Contraception,
chlamydia/gonorrhea, BV,
Family Planning
36-54 trichomoniasis, HSV, HPV, 22%
& STI
condoms, CDC 2026
Management
guidelines
Fibroids, ovarian cysts,
Benign
endometriosis, prolapse,
Gynecological
55-71 Bartholin cyst, 20%
Disorders &
postmenopausal bleeding,
Conditions
Pap results
Health Cultural competence, CVD
Promotion, Ethics prevention, folic acid, female
72-85 17%
& Cultural athlete triad, adolescent
Considerations consent, HT, bone health
,Content Area Questions Key Topics Weight
TOTAL 85 Comprehensive Coverage 100%
Question 1
According to the 2026 ACOG cervical cancer screening guidelines, what is the
recommended screening approach for average-risk individuals aged 30-65
years?
A) Cervical cytology alone every 3 years
B) Primary high-risk HPV (hrHPV) screening every 5 years
C) Co-testing with cytology and HPV every 5 years
D) Annual cervical cytology
Rationale: According to the 2026 ACOG cervical cancer screening guidance,
individuals aged 30-65 years should undergo clinician-collected primary
hrHPV screening every 5 years, using FDA-approved tests. This represents a
shift from cytology-based to HPV-first screening strategies.
Question 2
For average-risk individuals aged 21-29 years, what is the current ACOG
recommendation for cervical cancer screening?
A) Cervical cytology alone every 3 years
B) Primary HPV screening every 5 years
C) Co-testing every 5 years
D) Annual screening
Rationale: The 2026 ACOG guidelines recommend that individuals aged 21-
29 years be screened with cervical cytology alone every 3 years. HPV
screening is not recommended as the primary method for this age group due
to the high rate of transient HPV infections that resolve spontaneously.
, Question 3
Which patient population is eligible for patient-collected samples for primary
HPV testing under the 2026 ACOG guidelines?
A) All patients aged 21-65 years
B) Average-risk patients aged 30-65 years
C) Patients with abnormal Pap results only
D) Patients with multiple sexual partners
Rationale: The 2026 ACOG guidelines include the option for average-risk
patients aged 30-65 years to collect their own samples for hrHPV primary
screening every 3 years. This is a significant update aimed at improving access
and equity in cervical cancer screening.
Question 4
What is the primary purpose of a clinical breast examination (CBE) in
women's health assessment?
A) To diagnose breast cancer definitively
B) To detect breast abnormalities and serve as an adjunct to screening
mammography
C) To replace mammography
D) To screen for ovarian cancer
Rationale: Clinical breast examination is performed to detect breast
abnormalities such as masses, skin changes, or nipple discharge. It serves as
an adjunct to screening mammography, not a replacement. Definitive
diagnosis requires biopsy and further testing.
Question 5
Which hormone is responsible for the proliferation of the endometrial lining
during the proliferative phase of the menstrual cycle?
A) Progesterone
B) Estrogen
